



 **Baruch S.  
BLUMBERG  
INSTITUTE**

**PENNSYLVANIA  
BIOTECHNOLOGY CENTER**

# ENTREPRENEUR SPOTLIGHT

*presented by Hatch Biofund*

**June 5, 2025**

**3-5 p.m. EDT**

*Three selected biopharma companies will  
compete to win a \$250,000 investment  
by Hatch Biofund!*

**HATCH**  
BIOFUND

# PROGRAM

# NOTES

**Welcome & Intro:** Lou Kassa, MPA, CEO , Hepatitis B Foundation,  
Pennsylvania Biotechnology Center (PABC) & Blumberg Institute

**Emcee:** Lorenzo Pellegrini, PhD, Managing Partner, Hatch Biofund

## Introduction of Panel

Eric Heil, MBA, Medical Excellence Capital

Mohamed Kashkoush, PharmD, Daiichi Sankyo

Kathie Jordan, PhD, Ben Franklin Technologies

## Company Presentations

MasterSwitch Bio, Bob Diamond, MD, and Topher Brooke

OCMS Bio, Paul Halpern, JD

## Break

### Company Presentation

Recombination Therapeutics, John Oates

## Voting

Please place the index card with the logo of the company  
you wish to vote for in the basket at the front of the room.

## Networking Hour

*The **winner** will be announced during the networking hour.*

# NOTES

# FEATURED COMPANY

## M a s t e r S w i t c h B i o

MasterSwitch Bio is an mRNA company that aims to develop transformational treatments for end stage liver disease (ESLD) with cirrhosis from MASH/metALD/ALD.

Their labs are based at the University of Pennsylvania and the University of Pittsburgh. Dr. Drew Weissman (Nobel for Medicine 2023) is our mRNA developer and co-founder.

Their science team has established a complete reversal of disease and cirrhosis in three ESLD cirrhotic models: rat, human hepatocyte, and whole explanted human livers.



**TOPHER BROOKE**

CEO & BOARD MEMBER



**BOB DIAMOND, MD**

CMO

# FEATURED COMPANY




Conventional discovery processes yield passable, sub-optimal antibody drugs. OCMS proprietary high throughput function first analysis cuts years from development time and millions from cost while creating the best possible next generation antibodies. OCMS first asset, an anti-RSV antibody, has reached the preclinical stage; the second, a muscle mass enhancer, is close behind; both have demonstrated materially superior clinically differentiated competitive profiles.



**PAUL HALPERN, JD**

FOUNDER, CEO AND MANAGING MEMBER



# BIOTECH INSIDERS

with Lou Kassa

From the PABC



Be sure to like & subscribe!

## Forward Together

Venable is proud to support the **11th Annual Entrepreneur Spotlight** as it showcases and supports efforts to advance biotechnology discoveries and develop the next generation of researchers.

**VENABLE** LLP

125  
YEARS  
young

Prajakta A. Sonaker, Ph.D.  
151 W. 42nd Street, New York, NY | Attorney advertising

FOX CHASE THERAPEUTICS DISCOVERY, INC.

**FCTDI**

Small-molecule drug and probe discovery company  
Based at the Pennsylvania Biotechnology Center  
Founded in 2008; have received 28 SBIRs/STTRs  
Total >\$45M in non-dilutive federal research funding  
Prepared ~16,000 New Chemical Entities (NCEs)  
Three NCEs are currently in human clinical trials



[www.fctdi.com](http://www.fctdi.com)



## FEATURED COMPANY

recombination  
THERAPEUTICS

Recombination Therapeutics is a precision oncology company on a mission to overcome drug resistance in genetically defined cancers. We target the DNA repair pathways that tumors hijack to survive and adapt — restoring sensitivity to standard treatments and extending the durability of response.

Our lead program, RTx-303, is a potentially best-in-class, oral Polθ inhibitor that eradicates BRCA-mutant tumors in preclinical models and overcomes resistance to PARP inhibitors, radiation, and chemotherapy.



**JOHN OATES**  
COFOUNDER & CEO



# PANELISTS



**ERIC HEIL, MBA**

*MANAGING PARTNER,  
MEDICAL EXCELLENCE  
CAPITAL*



**KATHIE JORDAN, PHD**

*MANAGING DIRECTOR,  
BEN FRANKLIN TECHNOLOGY  
PARTNERS*



**MOHAMED KASHKOUSH,  
PHARM D**

*ASSOCIATE DIRECTOR,  
DAIICHI SANKYO*

THIS EVENT IS PRESENTED BY



Hatch Biofund is a life sciences venture capital firm headquartered in the Philadelphia region and affiliated with the Pennsylvania Biotechnology Center in Doylestown, Pa. Hatch was formed to provide early-stage capital to promising local life science companies, along with access to deep industry expertise and physical platforms to help them realize their missions.



**LORENZO PELLEGRINI, PHD**

MANAGING PARTNER

Lorenzo has overall responsibilities for Hatch's investing and operating activities. He is a scientist, investor and entrepreneur with 30 years of experience in the life sciences and is committed to translating scientific discoveries into products that make a difference in patients' lives.